Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vonoprazan + amoxicillin + levofloxacin + bismuth
- Development stage
- Unknown
- Lead developer
- Yanqing Li
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug combination is a quadruple therapy regimen designed for the eradication of *Helicobacter pylori* infection. It consists of vonoprazan, a potassium-competitive acid blocker (P-CAB) that provides rapid and sustained gastric acid suppression; amoxicillin, a broad-spectrum beta-lactam antibiotic; levofloxacin, a fluoroquinolone antibiotic; and a bismuth compound, which provides direct antimicrobial effects and mucosal protection. This specific regimen is being evaluated in clinical trials led by Yanqing Li at Shandong University to compare its efficacy and safety against vonoprazan-based dual therapy. The inclusion of vonoprazan instead of a traditional proton pump inhibitor (PPI) aims to achieve more stable acid inhibition, potentially improving the stability and efficacy of the co-administered antibiotics.
- Other names
- vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapyVBQTVALB
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)Topo IV (Bacterial Topoisomerase IV)DNA gyrasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on vonoprazan + amoxicillin + levofloxacin + bismuth.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vonoprazan + amoxicillin + levofloxacin + bismuth.